Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
17503results about "Biological material analysis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Zero-mode clad waveguides for performing spectroscopy with confined effective observation volumes
InactiveUS6917726B2Effective volumeEasy to useMicrobiological testing/measurementBiological material analysisAnalyteSpectroscopy
The present invention is directed to a method and an apparatus for analysis of an analyte. The method involves providing a zero-mode waveguide which includes a cladding surrounding a core where the cladding is configured to preclude propagation of electromagnetic energy of a frequency less than a cutoff frequency longitudinally through the core of the zero-mode waveguide. The analyte is positioned in the core of the zero-mode waveguide and is then subjected, in the core of the zero-mode waveguide, to activating electromagnetic radiation of a frequency less than the cut-off frequency under conditions effective to permit analysis of the analyte in an effective observation volume which is more compact than if the analysis were carried out in the absence of the zero-mode waveguide.
Owner:CORNELL RES FOUNDATION INC
Integrated Lancing and Measurement Device
InactiveUS20080017522A1Accurate and efficient measurementLower the volumeBioreactor/fermenter combinationsBiological substance pretreatmentsAnalyteMeasurement device
Owner:ABBOTT DIABETES CARE INC
Methods and agents for screening for compounds capable of modulating gene expression
InactiveUS20050048549A1Modulate expressionLibrary screeningTissue cultureRegulator geneProtein level
The invention relates to the fields of screening assays, compounds, and methods for altering gene expression and protein levels. In particular, the invention includes assays to screen for agents capable of modulating gene expression in a UTR-dependent manner and agents capable of modulating gene expression.
Owner:PTC THERAPEUTICS INC
Novel proteins with targeted binding
InactiveUS20050089932A1Stimulate and inhibit activityEasy screeningPeptide librariesPeptide/protein ingredientsMonomerComputational biology
Methods for identifying discrete monomer domains and immuno-domains with a desired property are provided. Methods for generating multimers from two or more selected discrete monomer domains are also provided, along with methods for identifying multimers possessing a desired property. Presentation systems are also provided which present the discrete monomer and / or immuno-domains, selected monomer and / or immuno-domains, multimers and / or selected multimers to allow their selection. Compositions, libraries and cells that express one or more library member, along with kits and integrated systems, are also included in the present invention.
Owner:AMGEN MOUNTAIN VIEW
Identification and engineering of antibodies with variant Fc regions and methods of using same
ActiveUS20050037000A1High affinityAltered affinityAntibacterial agentsSenses disorderTherapeutic antibodyWild type
The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcgammaRIIA and / or FcgammaRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcgammaR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
Owner:MARCOGENICS INC +1
Identification and engineering of antibodies with variant Fc regions and methods of using same
ActiveUS7355008B2Function increaseGood curative effectAntibacterial agentsSenses disorderTherapeutic antibodyEffector cell
Owner:MARCOGENICS INC +1
Optical determination of ph and glucose
InactiveUS20080188722A1Biological material analysisAnalysis by electrical excitationAnalyteSingle indicator
Embodiments of the present invention are directed to an optical sensor capable of measuring two analytes simultaneously with a single indicator system. In preferred embodiments, the sensor comprises a fluorescent dye having acid and base forms that facilitate ratiometric pH sensing, wherein the dye is further associated with a glucose binding moiety and configured to generate a signal that varies in intensity with the concentration of glucose.
Owner:MEDTRONIC MIMIMED INC
Compositions and methods for treating and diagnosing cancer
InactiveUS20070105133A1High of deathHigh riskMicrobiological testing/measurementBiological material analysisCancer metastasisSolid tumor
The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles and signatures associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. More particularly, the present invention identifies two profiles of cancer stem cells useful for the diagnosis, characterization, and treatment of cancer and cancer metastases. The invention also provides a variety of reagents such as stem cell gene signatures for use in the diagnosis and management of cancer.
Owner:RGT UNIV OF MICHIGAN
Monoclonal antibodies and detection methods for phosphinothricin-N-acetyl-transferase enzyme
ActiveUS9371394B2Immunoglobulins against bacteriaBiological material analysisN-acetyltransferaseAcetyltransferase
Owner:CORTEVA AGRISCIENCE LLC
Monoclonal antibodies to hepatocyte growth factor
InactiveUS7220410B2Animal cellsBiological material analysisMonoclonal antibodyHepatocyte growth factor
The present invention is directed toward a neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
Owner:GALAXY BIOTECH LLC
Antibodies to insulin-like growth factor I receptor
Owner:AMGEN FREMONT INC +1
Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
ActiveUS20050084506A1Enhancing savory tasteIncrease sweet tasteBiocideCosmetic preparationsMonosodium glutamateSalty taste
The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers,—savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.
Owner:SENOMYX INC
Method for differentially quantifying naturally processed hla-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
ActiveUS20130096016A1Efficient use ofBiological material analysisLibrary member identificationDiseaseAntigen
Owner:IMMATICS BIOTECHNOLOGIES GMBH
Bacillus thuringiensis CryET29 compositions toxic to coleopteran insects and ctenocephalides SPP
InactiveUS6093695ARemarkable insecticidal activityGood reproducibilityBiocideBacteriaBacillus thuringiensisCtenocephalides felis felis
Disclosed is a novel delta -endotoxin, designated CryET29, that exhibits insecticidal activity against siphonapteran insects, including larvae of the cat flea (Ctenocephalides felis), as well as against colcopteran insects, including the southern corn rootworm (Diabrotica undecimpunctata), western corn rootworm (D. virgifera), Colorado potato beetle (Leptinotarsa decemlineata), Japanese beetle (Popillia japonica), and red flour beetle (Tribolium castaneur). Also disclosed are nucleic acid segments encoding CryET29, recombinant vectors, host cells, and transgenic plants comprising a cryET29 DNA segment. Methods for making and using the disclosed protein and nucleic acid segments are disclosed as well as assays and diagnostic kits for detecting cryET29 and CryET29 sequences in vivo and in vitro.
Owner:MONSANTO TECH LLC
Waveguides for performing spectroscopy with confined effective observation volumes
InactiveUS7013054B2Effective volumeEasy to useCladded optical fibreMicrobiological testing/measurementAnalyteSpectroscopy
The present invention is directed to a method and an apparatus for analysis of an analyte. The method involves providing a zero-mode waveguide which includes a cladding surrounding a core where the cladding is configured to preclude propagation of electromagnetic energy of a frequency less than a cutoff frequency longitudinally through the core of the zero-mode waveguide. The analyte is positioned in the core of the zero-mode waveguide and is then subjected, in the core of the zero-mode waveguide, to activating electromagnetic radiation of a frequency less than the cut-off frequency under conditions effective to permit analysis of the analyte in an effective observation volume which is more compact than if the analysis were carried out in the absence of the zero-mode waveguide.
Owner:CORNELL RES FOUNDATION INC
Microfluidic device for cell separation and uses thereof
ActiveUS20060134599A1Simple methodBioreactor/fermenter combinationsMaterial nanotechnologyAntigenMembrane permeabilization
The invention features methods for separating cells from a sample (e.g., separating fetal red blood cells from maternal method begins with the introduction of a sample including cells into one or more microfluidic channels. In one embodiment, the device includes at least two processing steps. For example, a mixture of cells is introduced into a microfluidic channel that selectively allows the passage of a desired type of cell, and the population of cells enriched in the desired type is then introduced into a second microfluidic channel that allows the passage of the desired cell to produce a population of cells further enriched in the desired type. The selection of cells is based on a property of the cells in the mixture, for example, size, shape, deformability, surface characteristics (e.g., cell surface receptors or antigens and membrane permeability), or intracellular properties (e.g., expression of a particular enzyme).
Owner:THE GENERAL HOSPITAL CORP
Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
A method for identifying nucleic acid ligands to target molecules using the SELEX procedure wherein the candidate nucleic acids contain photoreactive groups and nucleic acid ligands identified thereby are claimed. The complexes of increased affinity nucleic acids and target molecules formed in the procedure are crosslinked by irradiation to facilitate separation from unbound nucleic acids. In other methods partitioning of high and low affinity nucleic acids is facilitated by primer extension steps as shown in the figure in which chain termination nucleotides, digestion resistant nucleotides or nucleotides that allow retention of the cDNA product on an affinity matrix are differentially incorporated into the cDNA products of either the high or low affinity nucleic acids and the cDNA products are treated accordingly to amplification, enzymatic or chemical digestion or by contact with an affinity matrix.
Owner:SOMALOGIC INC
Microfluidic device for cell separation and uses thereof
ActiveUS20070172903A1Simple methodMaterial nanotechnologyBioreactor/fermenter combinationsAntigenCell separation
Owner:THE GENERAL HOSPITAL CORP
Antagonist antibody for the treatment of cancer
ActiveUS20100047257A1High degreeStrong cytotoxicitySugar derivativesBiological material analysisSynovial sarcomaAntibody fragments
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit A class of Eph receptors, antagonize the effects of growth factors on the growth and survival of tumor cells, and which have minimal agonistic activity or are preferentially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of A class of Eph receptors, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of A class of Eph receptors. Also provided are cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the A class of Eph receptors.
Owner:SANOFI SA
Bacillus thuringiensis CryET29 compositions toxic to coleopteran insects and Ctenocephalides SPP
InactiveUS6537756B1Remarkable insecticidal activityGood reproducibilityBiocideBacteriaDelta endotoxinCtenocephalides felis felis
Disclosed is a novel delta-endotoxin, designated CryET29, that exhibits insecticidal activity against siphonapteran insects, including larvae of the cat flea (Ctenocephalides felis), as well as against coleopteran insects, including the southern corn rootworm (Diabrotica undecimpunctata), western corn rootworm (D. virgifera), Colorado potato beetle (Leptinotarsa decemlineata), Japanese beetle (Popillia japonica), and red flour beetle (Tribolium castaneum). Also disclosed are nucleic acid segments encoding CryET29, recombinant vectors, host cells, and transgenic plants comprising a cryET29 DNA segment. Methods for making and using the disclosed protein and nucleic acid segments are disclosed as well as assays and diagnostic kits for detecting cryET29 and CryET29 sequences in vivo and in vitro.
Owner:MONSANTO TECH LLC
Methods of diagnoisis, prognosis and treatment of cardiovascular disease
InactiveUS20030232385A1Improve accuracyHigh activityBiological material analysisDead animal preservationVascular diseaseChronic inflammatory disease
The invention provides methods for diagnosis or prognosis of cardiovascular disease involving the detection of an elevated amount of MIC-1 in a test body sample. The invention also provides methods for treatment of cardiovascular disease and other chronic inflammatory disease.
Owner:ST VINCENTS HOSPITAL SYDNEY
Method of determining a complete blood count and a white blood cell differential count
ActiveUS20090269799A1Improve accuracyLow costBioreactor/fermenter combinationsTelevision system detailsWhite blood cellBody fluid
Systems and methods analyzing body fluids such as blood and bone marrow are disclosed. The systems and methods may utilize an improved technique for applying a monolayer of cells to a slide to generate a substantially uniform distribution of cells on the slide. Additionally aspects of the invention also relate to systems and methods for utilizing multi color microscopy for improving the quality of images captured by a light receiving device.
Owner:ROCHE DIAGNOSTICS HEMATOLOGY INC
Materials and methods for the generation of fully 2'-modified nucleic acid transcripts
ActiveUS20070117112A1Increase productionImprove transcript yieldBacteriaSugar derivativesModified nucleosidesNucleic acid
Materials and methods are provided for producing aptamer therapeutics having fully modified nucleotide triphosphates incorporated into their sequence.
Owner:ARCHEMIX CORP
Antibodies specific for sclerostin and methods for increasing bone mineralization
ActiveUS20050106683A1Skeletal disorderImmunoglobulins against growth factorsGreek letter betaIncreased bone mineral density
Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
Owner:UCB PHARMA SA
Multivalent complexes, their production and method of use
Owner:PAUL SCHERRER INSTITUT
Methods and products related to the improved analysis of carbohydrates
The invention relates, in part, to the improved analysis of carbohydrates. In particular, the invention relates to the analysis of carbohydrates, such as N-glycans and O-glycans found on proteins and saccharides attached to lipids. Improved methods, therefore, for the study of glycosylation patterns on cells, tissue and body fluids are also provided. Information from the analysis of glycans, such as the glycosylation patterns on cells, tissues and in body fluids, can be used in diagnostic and treatment methods as well as for facilitating the study of the effects of glycosylation / altered glycosylation. Such methods are also provided. Methods are further provided to assess production processes, to assess the purity of samples containing glycoconjugates, and to select glycoconjugates with the desired glycosylation.
Owner:MASSACHUSETTS INST OF TECH +2
Biopolymer optical waveguide and method of manufacturing the same
ActiveUS20100063404A1Minimize negative impactImprove functional propertiesBiological material analysisMonocomponent fibroin artificial filamentFiberBiopolymer
A method of manufacturing a biopolymer optical waveguide includes providing a biopolymer, unwinding the biopolymer progressively to extract individual biopolymer fibers, and putting the unwound fibers under tension. The tensioned fibers are then cast in a different polymer to form a biopolymer optical waveguide that guides light due to the difference in indices of refraction between the biopolymer and the different polymer. The optical fibers may be used in biomedical applications and can be inserted in the body as transmissive media. Printing techniques may be used to manufacture the biopolymer optical waveguides.
Owner:TRUSTEES OF TUFTS COLLEGE
Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
ActiveUS7078180B2Sugar derivativesGenetic material ingredientsAbnormal tissue growthSpecific detection
Methods, compositions and kits which employ one or more ZEB specific detection reagents for detection and localization of ZEB associated molecules in tumor cells are disclosed. Also provided are methods for determining stage and progression of cancer in a mammal based on alterations in ZEB expression levels and subcellular localization. Also provided are methods for treating a cancer in a mammal by modulating ZEB expression levels and activity.
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA
Diagnostic device and method
InactiveUS6222619B1Fast resultsImprove the level ofRadiation pyrometrySpectrum investigationDiagnostic programReaction rate
A method and apparatus of diagnosing a cardiac disease state in as little as two minutes involving the utilization of an evanescent wave assay system in conjunction with a data acquisition and analysis procedure that monitors the precision of assay results in real time (i.e., while data is being acquired). The method includes diagnosing a disease state using a diagnostic procedure (e.g., an immunoassay) wherein the testing device informs the person conducting the test of the results of the test as soon as reliable test data is obtained (generally, <5% variation in the reaction rate of the assay). After which point, the diagnostic procedure may be terminated.
Owner:UNIV OF UTAH RES FOUND
Popular searches
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com